Exact Sciences
EXAS
#1153
Rank
A$28.91 B
Marketcap
A$152.40
Share price
0.24%
Change (1 day)
57.82%
Change (1 year)
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.

Exact Sciences (EXAS) - Total debt

Total debt on the balance sheet as of September 2025 : A$3.79 Billion

According to Exact Sciences's latest financial reports the company's total debt is A$3.79 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exact Sciences - Total debt on balance sheet (from 2009 to 2025)

Total debt by year

Year Total debt Change
2024-12-31A$4.42 B18.11%
2023-12-31A$3.74 B4.29%
2022-12-31A$3.59 B9.43%
2021-12-31A$3.28 B8.41%
2020-12-31A$3.03 B122.21%
2019-12-31A$1.36 B39.42%
2018-12-31A$0.97 B17060.9%
2017-12-31A$5.7 M-25.18%
2016-12-31A$7.62 M-7.72%
2015-12-31A$8.25 M127.25%
2014-12-31A$3.63 M-25.76%
2013-12-31A$4.89 M148.85%
2012-12-31A$1.96 M101.68%
2011-12-31A$0.97 M-0.93%
2010-12-31A$0.98 M-55.52%
2009-12-31A$2.21 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Myriad Genetics
MYGN
A$0.31 B-91.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Antares Pharma
ATRS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Veracyte
VCYT
A$60.91 M-98.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Biocept
BIOC
A$17.45 M-99.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$38.44 B 912.60%๐Ÿ‡ซ๐Ÿ‡ท France